NASDAQ · ABPWW
Abpro Holdings Inc
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Aug 15, 2026, 7:51 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.4M
- P/E ratio
- -0.05
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 7.89K
- Avg. volume
- 24.52K
Price performance
ABPWW price history
1M range · 0 trading sessions · Daily adjusted prices
ABPWW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ABPWW news
The latest Smart Investors Daily articles mentioning ABPWW.
Stock researchCompany · Overview
ABPWW research
Overview
Company profile and research snapshot.
Company profile
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
